
|Videos|September 9, 2022
Use of PARP Inhibitors in Breast Cancer: Implications for Pharmacy Practice
About 1 in 8 women in the United States will develop breast cancer in their lifetime. Overall mortality for breast cancer has decreased over the years with the addition of complex treatment, such as PARP inhibitors. The webcast discusses this class of medications and see how they fit into the treatment paradigm for breast cancer.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
















































































































































































































